Up-regulation of MT2A, the most abundant of these, is associated with more aggressive breast cancer and poor prognosis [41], and it is reported that the over-expression of metallothioneins predicts resistance to doxorubicin [42]. The gene discussed is MT2A; the disease is breast carcinoma.